{
    "clinical_study": {
        "@rank": "97544", 
        "acronym": "JET-HCC", 
        "arm_group": [
            {
                "arm_group_label": "ARQ 197", 
                "arm_group_type": "Experimental", 
                "description": "Daily oral dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Daily oral dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with\n      hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic\n      chemotherapy regimen including sorafenib."
        }, 
        "brief_title": "A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent form\n\n          -  \u226520 years old\n\n          -  Inoperable HCC which is not eligible for locoregional therapy\n\n          -  Diagnosed as c-Met high in tumor sample\n\n          -  Radiographic progression is confirmed during or after systemic chemotherapy including\n             sorafenib, or those who are intolerance to the chemotherapy.\n\n          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1\n\n          -  Child-Pugh Class A\n\n          -  Having measurable target lesions which are defined by Response Evaluation Criteria in\n             Solid Tumors (RECIST) version 1.1,\n\n          -  Negative pregnancy test results\n\n          -  Adequate organ function\n\n          -  Life expectancy of at least 12 weeks\n\n        Exclusion Criteria:\n\n          -  More than 2 prior systemic chemotherapy.\n\n          -  Prior therapy of c-Met inhibitor (including antibody)\n\n          -  Any systemic therapy within \u22642 weeks prior to the randomization\n\n          -  Locoregional therapy within \u22644 weeks prior to randomization.\n\n          -  Major surgery within \u22644 weeks prior to the randomization\n\n          -  Concurrent cancer within \u22645 years prior to the randomization\n\n          -  History of cardiac diseases\n\n          -  Active clinically serious infections defined as \u2265 Grade 3 according to Common\n             Toxicity Criteria for Adverse Effects (CTCAE) 4.0\n\n          -  Any psychological disorder affecting Informed Consent\n\n          -  Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody\n\n          -  Blood or albumin transfusion within \u226414 days prior to the screening test\n\n          -  Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus\n             (HCV)\n\n          -  Symptomatic brain metastases\n\n          -  History of liver transplantation\n\n          -  Inability to swallow oral medications\n\n          -  Confirmed interstitial lung disease\n\n          -  Pleural effusion and/or clinically significant ascites\n\n          -  Pregnancy or breast-feeding\n\n          -  Without consent to effective single or combined contraceptive methods"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029157", 
            "org_study_id": "ARQ 197-009"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARQ 197", 
                "intervention_name": "ARQ197", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "clinical.info@kyowa-kirin.co.jp", 
                "last_name": "KYOWA HAKKO KIRIN"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Cancer Centers in Japan"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy", 
        "overall_contact": {
            "email": "clinical.info@kyowa-kirin.co.jp", 
            "last_name": "KYOWA HAKKO KIRIN"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival will be compared between ARQ 197 group and Placebo group, to prove the efficacy of ARQ 197 in the population.", 
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Estimated median of 8-12 weeks in PFS"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The date of the events was followed every three months after the end of the treatments of the study drug.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "Estimated median of 24 weeks in overall survival"
        }, 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}